Pulmotect, Inc.
  • Home
  • About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Overview
    • Our Science
    • Our Pipeline
    • Published Journal Articles
  • News
  • Contact Us

  • Houston biopharmaceutical company brings on new CEO to grow company
    InnovationMap - Oct 2019
  • Dr. Colin Broom joins Pulmotect, Inc. as CEO
  • AstraZeneca VP Kumar Srinivasan Joins Pulmotect, Inc. Board of Directors
  • Pulmotect Completes Second Clinical Trial, Closes $1.75M Investment, Earns $1M NIH Award
  • Pulmotect Awarded $3 Million NIH Grant to Fund Infection Prevention Drug Trials
  • Pulmotect Completes Clinical Testing, Receives CPRIT Funding for Continued Development
  • Pulmotect Wins Southeast BIO Early Stage Shootout
  • CPRIT Awards Pulmotect $7.1 Million to Develop Novel Immune Stimulant
  • Texas Emerging Technology Fund Makes Investment in Pulmotect
  • Lab Finds Fast Way to Boost Immunity
  • Breathe Deep Against Bacteria
  • Germ-Fighting Inhaler Could Fend Off Bioterror Agents
  • Aerosol Launches Immune Response in Lungs to Wipe Out Lethal Infections
  • Nasal Spray Protects Against Deadly Lung Infections
  • Aerosol Immune Builder May Prevent Pneumococcal Pneumonia in Cancer Patients
  • Aerosol Therapy May Offer Hope to Infection-Prone Patients
  • In Our Labs: Wiping Out Lethal Infections
  • Tour of Texas: Surge Ventures, Dell, Fannin Innovation, CellRight
    Xconomy - April 2016
  • Pulmotect Completes Second Clinical Trial, Obtains Funding
    Pharmacy Choice - April 2016
  • Synthetic inhaled drug prevents pneumonia in cancer patients
    Scrip Pharma Intelligence - December 2015

Posts navigation

Older posts
Pulmotect Inc

3900 Essex Ln, Suite 575
Houston, TX 77027
Contact Us

© 2022
Pulmotect, Inc.